NCT02360007View on ClinicalTrials.gov

Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Opioid-related Disorders
Interventions
DRUG

Interim Buprenorphine Treatment (IBT)

"The Interim Buprenorphine Treatment (IBT) includes:~1. Buprenorphine (BUP)~2. Computerized adherence monitoring (CAM): BUP will be dispensed via a portable device that makes each day's dose available only at a predetermined time.~3. Mobile health clinical support: An Interactive Voice Response (IVR) system to deliver clinical support~4. Urinalysis and adherence monitoring with participants contacted via IVR for random call-backs~5. HIV+Hepatitis Education delivered via iPad"

Trial Locations (1)

05401

Substance Abuse Treatment Center, University of Vermont, Burlington

All Listed Sponsors
lead

University of Vermont Medical Center

OTHER

NCT02360007 - Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access | Biotech Hunter | Biotech Hunter